Detection of the Epstein-Barr virus in blood and bone marrow mononuclear cells of patients with aggressive B-cell non-Hodgkin's lymphoma is not associated with prognosis

Oncology Letters

Volumn 4, Issue 6, 2012, Pages 1285-1289

  Marques, Herlander ^a,b   Catarino, Raquel ^c   Domingues, Nelson ^d   Barros, Eliane ^c   Portela, Catarina ^b   Almeida, Maria Inês ^a   Costa, Sandra ^a   Reis, Rui Manuel ^a,e   Medeiros, Rui ^c,f   Longatto Filho, Adhemar ^a,g  

^a UNIVERSITY OF MINHO   (Portugal)

^b HOSPITAL DE BRAGA   (Portugal)

^c PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^d Oncology Hematology Department   (Portugal)

^e BARRETOS CANCER HOSPITAL   (Brazil)

^f Pessoa University   (Portugal)

^g UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Diffuse large B cell lymphoma; Epstein barr virus; Mononuclear cells; non Hodgkin's lymphoma; non Hodgkin's lymphoma risk factors; Rituximab

Indexed keywords

BETA 2 MICROGLOBULIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; LACTATE DEHYDROGENASE; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ADULT; ARTICLE; BLOOD; BONE MARROW; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; EPSTEIN BARR VIRUS; FEMALE; GENE; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; RISK FACTOR; SCORING SYSTEM; SURVIVAL RATE; TREATMENT RESPONSE; VIRUS DETECTION; VIRUS GENOME;

EID: 84867240731     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.913     Document Type: Article

References (21)

1. Cohen JI: Epstein-Barr virus infection. N Engl J Med 343: 481-492, 2000.
2. Thorley-Lawson DA and Gross A: Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med 350: 1328-1337, 2004.
3. Kelly G, Bell A and Rickinson A: Epstein-Barr virus-associated Burkitt lymphomagensis selects for downregulation of the nuclear antigen EBNA2. Nat Med 8: 1098-1104, 2002.
4. Banks PM and Warnke RA: Mature T-cell and NK-cell neoplasms. In: WHO Classification of Tumors: Pathology and Genetics of Tumours of Hematopoetic and Lymphoid Tissues. Jaffe ES, Harris NL, Stein H and Vardiman JW (eds). IARC Press, Lyon, pp 189-230, 2001.
5. Kuzushima K, Kimura H, Hoshino Y, et al: Longitudinal dynamics of Epstein-Barr virus-specific cytotoxic T lymphocytes during posttransplant lymphoproliferative disorder. J Infect Dis 182: 937-940, 2000.
6. Hamilton-Dutoit SJ, Raphael M, Audouin J, et al: In situ demonstration of Epstein-Barr virus small RNAs (EBER 1) in acquired immunodeficiency syndrome-related lymphomas: correlation with tumor morphology and primary site. Blood 82: 619-624, 1993.
7. Oyama T, Yamamoto K, Asano N, et al: Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients. Clin Cancer Res 13: 5124-5132, 2007.
8. Ambinder RF and Mann RB: Detection and characterization of Epstein-Barr virus in clinical specimens. Am J Pathol 145: 239-252, 1994.
9. Hassan R, White LR, Stefanoff CG, et al: Epstein-Barr (EBV) detection and typing by PCR: a contribution to diagnostic screening of EBV-positive Burkitt's lymphoma. Diagn Pathol 1: 17-23, 2006.
10. Morales D, Beltran B, De Mendoza FH, et al: Epstein-Barr virus as a prognostic factor in de novo nodal diffuse large B-cell lymphoma. Leuk Lymphoma 51: 66-72, 2010.
11. Park S, Lee J, Ko YH, et al: The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood 110: 972-978, 2007.
12. Paydas S, Ergin M, Seydaoglu G, et al: Prognostic significance of angiogenic/lymphangiogenic, anti-apoptotic, inflammatory and viral factors in 88 cases with diffuse large B cell lymphoma and review of the literature. Leuk Res 33: 4117-4126, 2009.
13. Yoshino T, Nakamura S, Matsuno Y, et al: Epstein-Barr virus involvement is a preditive factor for the resistance to chemoradiotherapy of gastric diffuse large B-cell lymphoma. Cancer Sci 97: 163-166, 2006.
14. Tierney RJ, Steven N, Young LS and Rickinson AB: Epstein-Barr virus latency in blood mononuclear cells: Analysis of viral gene transcription during primary infection and in the carrier state. J Virol 68: 7374-7385, 1994.
15. Decker LL, Klaman LD and Thorley-Lawson DA: Detection of the latent form of Epstein-Barr virus DNA in peripheral blood of healthy individuals. J Virol 70: 3286-3299, 1996.
16. Swerdlow SH, Campo E, Harris NE, et al (eds): WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue. 4th edition. IARC Press, Lyon, 2008.
17. Heid CA, Stevens J, Livak KJ and Williams PM: Real time quantitative PCR. Genome Res 6: 986-994, 1996.
18. Gibson SE and Hsi ED: Epstein-Barr virus-positive B-cell lymphoma of elderly at a United States tertiary medical center: an uncommon aggressive lymphoma with a nongerminal center B-cell phenotype. Hum Pathol 40: 653-661, 2009.
19. Hoeller S, Tzankov A, Pileri SA, et al: Epstein-Barr virus-positive diffuse large B cell lymphoma in elderly patients is rare in Western populations. Hum Pathol 41: 352-357, 2010.
20. Mounier N, Briere J, Gisselbrecht C, et al: Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 101: 4279-4284, 2003.
21. Milpied N, Vasseur B, Parquet N, et al: Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients. Ann Oncol 11: 113-116, 2000.